NRX: Kadima Neuropsychiatry Institute Expected First Acquisition

 

• Kadima Neuropsychiatry Institute in La Jolla, CA to serve as flagship for an international network of clinics dedicated to treating depression and PTSD
• Kadima's founder, David Feifel, MD, PhD, Professor Emeritus of Psychiatry at University of California San Diego, a pioneer in advanced interventional treatments for neuropsychiatric conditions such as depression and PTSD, to join Hope as Chief Medical Innovation Officer
• Kadima is a leading investigative site for CNS and psychedelic research, and has served as the lead site in nearly all major clinical trials in this area
• Acquisition expected to be immediately accretive to revenue and EBITDA for NRx

https://www.prnewswire.com/news-releases/hope-therapeutics-inc-and-nrx-pharmaceuticals-inc-nasdaqnrxp-announce-kadima-neuropsychiatry-institute-as-the-expected-first-acquisition-for-its-international-network-of-interventional-psychiatry-clinics-302341062.html